Kathryn Oakes Senior Nurse for Viral Hepatitis Kings College Hospital November 2011
|
|
- April Harper
- 5 years ago
- Views:
Transcription
1 Kathryn Oakes Senior Nurse for Viral Hepatitis Kings College Hospital November 2011
2 Background to the AVT outreach project Referring into the service and the role of the Physical Health Harm Reduction Nurse (PHHRN) Milestones Referral, assessment and treatment data Substance misuse levels Barriers to project success
3 HCV - 85% chronicity rate with 20% cirrhosis 1 rate1 and 3-5% risk per annum HCC2 HCV most common cause transplantation in western population3 40% transplants at KCH = 168 pa Mortality rate planned to triple by with an 8 billion economic burden to the NHS5 HCV prevalence in IDU s up to 66% in London6 Population reluctant to attend secondary care7 LHH 1000 to 1200 clients with new p.w 1. Alter MJ Semin Liver Dis 1995; 15:Management of Hepatitis C NIH Consensus Statement 1997; March 24-26:15(3). 2. Cabrera R, Nelson D R. (2009) Review article: the management of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 31: Lodato et al. (2008) Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Alimentary Pharmacology and Therapeutics, 28: Cheruvu et al. (2007) Strategies to control hepatitis C infection among injection drug users. Hot Topics in Viral Hepatitis, 6: British Liver Trust. (2010) Facts about Liver disease (online). 6. Health Protection Agency. (2009) Shooting up. Infections among injecting drug users in the United Kingdom 2008: An update. 7. Foster G. (2008) Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy? Addiction, 103:
4 Kosh Agarwal, Lead Consultant for VHS, KCH Mike Kelleher, Clinical lead for LA Kathryn Oakes, Senior Nurse VHS, KCH Mick Collins, Borough Lead for LA Tony Docherty, Deputy borough Lead for LA Mags O Sullivan, Kristen Stone PHHRN and Integrated Care Nurses, VHS KCH Martin McCusker, service user Dee Cunniffe, Reckitt Benckiser Fenella Jolly, Team Leader BBV/Homeless Team
5 Alcohol intake does not exceed 40 units weekly Ideally no IV Crack Cocaine Client agrees to regularly attend appointments and consents to appropriate drug screening Stable housing with fridge Agree to enter needle exchange programme Stable from a psychological perspective
6 Client tests Positive HCV/HBV Is Client stable? Assessment of client stability re: addiction issues Yes Referral to Hepatitis Team No Contact Hep CNS team for advice Appointment for screening and education with Hep CNS within 14 days REFERRAL Client not suitable for AVT Client suitable for AVT PATHWAY Referral back to Drug/alcohol advisory service Hepatology review Cirrhotic or HBV offer Follow up at Kings Delivery AVT16 to 72 weeks
7 Contact known HCV RNA positive clients BBV testing and HBV vaccination Work with the substance misuse teams to identify clients for treatment and co-ordinate referral into the service Engagement of clients, education and harm reduction advice Acts as a resource and contact for patients on treatment and attends all KCH appointments Strategic role in service development
8 Action plan formulated Working group established Operational Policy and SLA finalised Meet service users Initial appt PHHRN Transfer of PHHRN post 1 st assessment/ education clinic PHHRN appointed Jan 2009 June 2010 Feb 2011 May 2011 July2011 Sept 2011 First treatment clinic First medical clinic RAISING AWARENESS & EDUCATION
9 ReferralSource Number patients Referred to Kings Keyworkers at LHH (29%) FenellaJolly 2 1 (50%) DRR 4 0 (0%) RIOTT at MH 8 8 (100%) Triage 15 0 (0%) Previous bloods (Fenella) 9 1 (11%) WHD + keyworker 3 2 (66%) WHD 3 1 (33%) Relative 1 0 (0%) Total 133 * 39 * 81 known HCV, 52 tested 25 HCV RNA pos and 26 tested RNA negative, 1 HCV ab pos on DBST and refusing venous sample Data collection period 29/06/2011 to 26/10/2011
10 39 Booked for assessment and education with KCH viral hepatitis CNS team 17 completed assessment 16 booked for future assessments 3 DNA d& 1 declined assessment 1 assessment delayed social issues 1 removed unfavourable genotype and IL28
11 Genotype Disease stage
12
13 Patient Genotype Treatment week Response One 1 non cirrhotic 9 Complete EVRTW9 Two 1a non cirrhotic 14 RVR Three 1b cirrhotic 0 N/A Four 3a non cirrhotic 19 Complete EVRTW9 Five 3 cirrhotic 5 RVR Six 3a non cirrhotic 14 RVR Seven 3 non cirrhotic 5 5 log drop at TW4 to 9.92 E1 IU/Ml Eight 3 non cirrhotic 5 3 log drop at TW4 to 1.06 E2 IU/Ml Nine 3 non cirrhotic 3 N/A
14 %
15 Alcohol Number Abstinent Substitute Drug Level of drug use Number Substitute Units p.w drugs Prescribing use Prescribing (3 OT) 3 RIOTT 11 Cannabis 3 1 RIOTT 1 No substitutes Heroin or crack smoked once a week 4 (3 OT) 10 substitute 11 substitute IV heroin once or twice a week 1 (1 OT) IV heroin once to three times a week 1 (1 OT) IV heroin two to four times a week RIOTT 4 Cannabis 1 2 substitute Occasional speed 1 (1 OT) Heroin or crack smoked once a week 1 IV heroin use and crack smoked 1-2 wk RIOTT 1 Cannabis and smoking crack 1 RIOTT 2 substitute Heroin/IV skin popping 3 times a week 1 1 substitute Total
16 Lack of awareness amongst substance misuse population; concerns about the side effects; previous experiences in secondary care; chaotic lifestyles competing priorities Resource and time needed for engagement, education and referral Working across two sites; IT, medication dispensing, transportation samples, honorary contracts Different cultures and organisational changes
17 Project is a work in progress We have learnt a lot about this population and working across sites/specialities To date a model that integrates specialist viral hepatitis and addiction services appears to work well Treatment outcomes will give us more insight into the effectiveness of the model The role of the PHHRN has been essential to engage clients and bridge services
Hepatitis C. Request a Test. Benefits of testing in AOD services to improve treatment uptake
Hepatitis C Request a Test Benefits of testing in AOD services to improve treatment uptake Jenny Bourke Clinical Nurse Specialist Hepatitis C Community Clinic Christchurch About Hepatitis C Hepatitis is
More informationHA Corporate Scholarship Program:
HA Corporate Scholarship Program: Substance Abuse Service in Psychiatry Ronnie Pao 02-10-10 The Maudsley Hospital Marina House Community Drug & Alcohol Team London Borough of Southwark Provides a Tier
More informationHepatitis C Strategy. About us. What is hepatitis C?
Hepatitis C Strategy About us We support people to take control of their lives and make positive changes. For fifty years we have made a difference to people who want to change their relationship with
More informationService Specification: Bristol and South Gloucestershire Specialist Substance Misuse Treatment Service January 2016
This specification is an annex to the Service Specification for the provision of Child and Adolescent Mental Health Services. It must be read along with the overarching specification which applies to all
More informationNotes Testing: Follow Up and Giving Results
As you do more tests it may become impractical to give all results face to face. You need to think of a system for calling in patients with a positive test promptly and without giving the result on the
More informationHEPATITIS C TREATMENT GUIDANCE
HEPATITIS C TREATMENT GUIDANCE These guidelines have been produced based on the NICE Guidance TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis c and the summaries of product
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 3
National Clinical Guidelines for the treatment of HCV in adults Version 3 January 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN
More informationSubstance Misuse in Older People
Substance Misuse in Older People Dr Tony Rao Consultant Old Age Psychiatrist, SLAM NHS Foundation Trust Visiting Researcher, Institute of Psychiatry, Neurology and Neuroscience Chair of Substance Misuse
More informationChronic hepatitis B virus (HBV)
Chronic hepatitis B virus (HBV) Information for patients This leaflet explains chronic hepatitis B virus, including how you may have become infected, the main symptoms and how it is treated. If you have
More informationTackling the problem of hepatitis C, substance misuse and health inequalities: a consensus for
Tackling the problem of hepatitis C, substance misuse and health inequalities: a consensus for London The London Joint Working Group for Substance Misuse and Hepatitis C (LJWG) Dr Kosh Agarwal, Consultant
More informationUpdate in hepatitis C virus infection
Update in hepatitis C virus infection Eoin Feeney Consultant in Infectious Diseases St. Vincent s University Hospital Overview Natural history Diagnosis, screening, staging Management Barriers going forward
More informationCircle Yes or No Y N. [If yes, skip to question 13 REAUTHORIZATION REQUESTS]
04/30/2014 Prior Authorization AETA BETTER HEALTH OF ILLIOIS MEDICAID Peginterferon (IL88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationHepatitis situation in the Republic of Macedonia
Hepatitis situation in the Republic of Macedonia Presented by Viktorija Chaloska Ivanova University Clinic of Gastroenterology Skopje, Republic of Macedonia Hepatitis Prevalence/incidence in Macedonia
More information6.1.2 Other multi-agency groups which feed into the ADP and support the on-going work includes:
6. ALCOHOL AND DRUGS PLANNING FRAMEWORK 6.1 Analysis of Local Position 6.1.1 The Alcohol and Drug Partnership (ADP) in Renfrewshire has responsibility for local planning of alcohol and drug services. ADPs
More informationResource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430
Putting NICE guidance into practice Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430 Published: January 2017 Summary Sofosbuvir velpatasvir is recommended as an option
More information4.0 Current Service Configuration
4.0 Current Service Configuration Adult addictions services are delegated to the Edinburgh Integration Joint Board (IJB) and the responsibility for planning and developing these services sits with the
More informationUrban Village Medical Practice Service Review An integrated model for high quality healthcare for homeless people in Manchester
An integrated model for high quality healthcare for homeless people in Manchester Urban Village Medical Practice Urban Village Medical Practice (UVMP) is a GP practice based at Ancoats Primary Care Centre
More informationModels of good practice in drug treatment in Europe. Project group
Models of good practice in drug treatment in Europe ( moretreat 2006329 ) Project group Hamburg, London, Rome, Stockholm, Vienna, Warsaw, Zurich Project duration: 17 months from April 2006 August 2008
More informationStrategies to enhance HCV testing, linkage to care and treatment
Strategies to enhance HCV testing, linkage to care and treatment STACEY B. TROOSKIN M D PHD DIREC TOR OF VIRAL HEPAT I T IS PROGRAMS PHILADELPHIA FIGHT COMMUNITY HEA LT H CENTERS PHILADELPHIA, PA Disclosures
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 4
National Clinical Guidelines for the treatment of HCV in adults Version 4 November 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN
More informationCABINET PROCURING A SUBSTANCE MISUSE & COMMUNITY TREATMENT SERVICE IN RUTLAND
CABINET Report No: 105/2017 PUBLIC REPORT 16 May 2017 PROCURING A SUBSTANCE MISUSE & COMMUNITY TREATMENT SERVICE IN RUTLAND Report of the Director of Public Health Strategic Aim: Safeguarding Key Decision:
More informationUpdate on Community-based harm reduction services in Nelson Mandela Bay 25/10/2018
Update on Community-based harm reduction services in Nelson Mandela Bay 25/10/2018 Overview Background to injecting drug use Overview of harm reduction Data on Hepatitis Summary of services provided by
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 5
National Clinical Guidelines for the treatment of HCV in adults Version 5 June 2018 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN co-ordinators
More informationprovides services for drug and alcohol users, families and carers.
provides services for drug and alcohol users, families and carers. Blenheim s mission is to end dependency by enabling people to change. Along the way we also improve people s health and quality of life
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationItem 4. Sexual Health and Blood Borne Virus Strategy Strategy for Sexual Health and Blood Borne Viruses. Background
Item 4 Strategy for Sexual Health and Blood Borne Viruses Background 1. In August 2011 the Scottish Government launched a joint Sexual Health and Blood Borne Virus Framework. This brought four policy areas
More informationEdinburgh Access Practice Hepatitis C Clinic Jessie Anderson, Kim McBeth, John Budd and Rebecca Martin
Edinburgh Access Practice Hepatitis C Clinic Jessie Anderson, Kim McBeth, John Budd and Rebecca Martin Content What is hepatitis C and why is it important? Brief overview of how the clinic works Have a
More informationEconomic issues in Hepatitis C. Richard Grieve London School of Hygiene and Tropical Medicine
Economic issues in Hepatitis C Richard Grieve London School of Hygiene and Tropical Medicine Acknowledgements Mild Hepatitis C study Principal Investigators: Howard Thomas, Janice Main Centre co-ordinators
More informationMidlands and East Hepatitis C Educational Event Summary Report
Midlands and East Hepatitis C Educational Event Summary Report Friday 10 th February 2017, Nottingham Background The Midlands and East Hepatitis C Educational Event took place on Friday 10 th February
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationHEPATITIS C: CANADIAN CONTEXT
1 OPTIMAL ADHERENCE DURING HCV TREATMENT AMONGST ACTIVE DRUG USERS IN A COMMUNITY-BASED PROGRAM IN TORONTO, CANADA KATE MASON RESEARCHER SEPTEMBER 8, 2016 HEPATITIS C: CANADIAN CONTEXT 250,000 Canadians
More informationHCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
More informationPrimary Care Services for blood borne viral hepatitis prevention, treatment and care
Primary Care Services for blood borne viral hepatitis prevention, treatment and care Author: Josie Smith, Marion Lyons Page 1 of 13 October 2006 Status : Final Contents: Page: Executive Summary 3 Introduction
More informationProject SUCCEED Scaling up Co Infection Care & Eliminating Ethnic Disparities 13 th Annual Iris House Women As the Face of AIDS Summit May 7th, 2018
Project SUCCEED Scaling up Co Infection Care & Eliminating Ethnic Disparities 13 th Annual Iris House Women As the Face of AIDS Summit May 7th, 2018 2 Project SUCCEED Team Natalie Octave, MPH, CHES Project
More informationThe Hepatitis C Action Plan for Scotland: Draft Guidelines for Hepatitis C Care Networks
The Hepatitis C Action Plan for Scotland: Draft Guidelines for Hepatitis C Care Networks Royal College of Physicians of Edinburgh Friday 12 October 2007 CONTENTS 1.0 ACCOUNTABILITY AND ORGANISATION 2.0
More informationHepatitis C treatment program improves access to housing, income and healthcare
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Hepatitis C treatment program improves access to housing, income and healthcare 13 July 2015 Despite high rates of hepatitis C virus (HCV)
More informationCocaine users: a special population? The evidence for policy and practice. SSA Conference 2005 Luke Mitcheson, South London and Maudsley NHS Trust
Cocaine users: a special population? The evidence for policy and practice SSA Conference 2005 Luke Mitcheson, South London and Maudsley NHS Trust Why might cocaine users be a Different drug? special population?
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationSection 7: Providing HCV testing and treatment to people who inject drugs
Section 7: Providing HCV testing and treatment to people who inject drugs Dr. Niklas Luhmann (Médecins du Monde) Training Hepatitis C and HR for PWUD, 9 th -13 th May 2016, Hanoi, Vietnam Learning objective
More informationThe forgotten group: a new HIV outbreak amongst people who inject drugs. Patricia Anderson Lead CNS BBV Brownlee Centre
The forgotten group: a new HIV outbreak amongst people who inject drugs Patricia Anderson Lead CNS BBV Brownlee Centre No conflicts to declare Potted History 1981 Modern wave of drug misuse Glasgow soared
More informationSubstance misuse among young people The data for
Substance misuse among young people The data for 28-9 EFFECTIVE TREATMENT CHANGING LIVES www.nta.nhs.uk Substance misuse among young people The data for 28-9 More teenagers are receiving help for drug
More informationHIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME
HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME Technical considerations and case definitions for VIRAL HEPATITIS SURVEILLANCE Dr Yvan J-F Hutin Global Hepatitis Programme 01 FOUR MAIN HEPATITIS VIRUSES
More informationTotal Payment for sponsored attendances by Healthcare Professionals: 182,677 ( 153,923 in 2013)
Gilead Sciences Ltd. 280 High Holborn London WC1V 7EE 31st March 2015 Relationships with Healthcare Professionals in the United Kingdom Gilead Sciences makes payments to Healthcare Professionals for consultancy
More informationPhysical Aspects of Substance Misuse in Older People. Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford
Physical Aspects of Substance Misuse in Older People Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford Areas to cover Hepatitis C Curable disease New drugs (goodbye interferon) Drug Interactions
More informationHCV ACTION EAST OF ENGLAND HEPATITIS C GOOD PRACTICE ROADSHOW, 9TH MAY 2017 SUMMARY REPORT
HCV ACTION EAST OF ENGLAND HEPATITIS C GOOD PRACTICE ROADSHOW, 9TH MAY 2017 SUMMARY REPORT Introduction With hepatitis C representing a significant public health concern in the Cambridge and East of England
More informationViral Hepatitis Burden and Policy Directions in the European Region of WHO
Viral Hepatitis Burden and Policy Directions in the European Region of WHO Dr Nedret Emiroglu WHO Regional Office for Europe Brussels 14-15 October 2010 Global Burden of Chronic Viral Hepatitis 2.7% all
More informationHepatitis C - Are we doing enough to diagnose, test and refer for treatment in primary care? Lonsdale Medical Centre a case example
Hepatitis C - Are we doing enough to diagnose, test and refer for treatment in primary care? Lonsdale Medical Centre a case example Chris Ford, Caitlin Chasser, Rita Alyward, Melanie McKay & Brian Whitehead
More informationAddiction and Substance misuse pathways
Addiction and Substance misuse pathways Gordon Morse Chief Medical Officer Turning Point UK Gordon Morse statement of interests Sole employer Turning Point Some unpaid advisory work to the Hepatitis C
More informationTemplate Control Page. Substance Misuse Newham Template Guide. Substance Misuse Newham. Date September 2015 DOCUMENT MANAGEMENT REVISION HISTORY
Template Control Page Substance Misuse Newham Template Guide Title Substance Misuse Newham Author CEG Status Active Date September 2015 DOCUMENT MANAGEMENT REVISION HISTORY Version Date Summary of Changes
More informationHertfordshire Young People s Substance Misuse Strategic Plan
Hertfordshire Young People s Substance Misuse Strategic Plan 2014 15 1 1. Introduction and context Young people misusing substances can cause harm to our communities through crime and antisocial behaviour,
More informationHorizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688
Horizon Scanning Centre November 2012 Faldaprevir with BI 207127 for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research
More informationTreatment guidance for Chronic Hepatitis C Infection
Treatment guidance for Chronic Hepatitis C Infection A meeting of the network was held on 11 April 2008 at which the current evidence base for hepatitis C was reviewed. These guidelines have been produced
More informationHCV Action and Bristol & Severn ODN workshop, 14 th September 2017: Summary report
HCV Action and Bristol & Severn ODN workshop, 14 th September 2017: Summary report About HCV Action HCV Action is a network, co-ordinated by The Hepatitis C Trust, that brings together health professionals
More informationGreater Manchester Commissioning Guidelines for Blood Borne Virus Prevention
Greater Manchester Commissioning Guidelines for Blood Borne Virus Prevention Endorsed by Greater Manchester Director of Public Health March 2011 Hepatitis Greater Manchester Hepatitis C Strategy Authors
More informationNHS FORTH VALLEY LOCAL ENHANCED SERVICE (2010) General Practitioner Prescribing Service (GPPS) Opiate Assisted Treatment Service Specification
NHS FORTH VALLEY LOCAL ENHANCED SERVICE (2010) Rationale General Practitioner Prescribing Service (GPPS) Opiate Assisted Treatment Service Specification Aims It is the responsibility of general practitioners
More information4 th largest seaside town in UK 2 nd most densely populated Most densely populated which is 100% seaside Typical presentation for a town of its
Glyn Halksworth 4 th largest seaside town in UK 2 nd most densely populated Most densely populated which is 100% seaside Typical presentation for a town of its scale. Or is it? Tourism and alcohol Regional
More informationCWP Drug & Alcohol Education Curriculum Overview
CWP Drug & Alcohol Education Curriculum Overview Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 1 Medicines and People Who Help Us Lesson 1: Staying Healthy Lesson 2: Medicines Lesson 3: Who gives us medicines?
More informationThe next steps
Greater Manchester Hepatitis C Strategy The next steps 2010-2013 Endorsed by GM Director of Public Health group January 2011 Hepatitis Greater Manchester Hepatitis C Strategy 1. Introduction The Greater
More informationPrevention Point Philadelphia
Integrating Hepatitis C Prevention, Care, Education, and Referrals in a Clinical & Social Service Setting By Iredia Olaye Primary Care & HCV Outreach, Linkage & Referral Specialist Prevention Point Philadelphia
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationin pregnancy Document Review History Version Review Date Reviewed By Approved By
GYNAECOLOGY/ ANTENATAL CARE WIRRAL WOMEN & CHILDREN S HOSPITAL Guideline No: Hepatitis B management in pregnancy VERSION 1 AMENDMENTS MADE: N/A DATE OF ISSUE: May 2012 DATE OF REVIEW: May 2015 REVIEW INTERVAL:
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationIntegrating hepatitis C treatment in a regional setting The Cairns Experience. DANA 2018 Morag Goodinson
Integrating hepatitis C treatment in a regional setting The Cairns Experience DANA 2018 Morag Goodinson I would like to acknowledge the Traditional Owners of the land, and pay respect to Elders past, present
More informationBARNSLEY METROPOLITAN BOROUGH COUNCIL
BARNSLEY METROPOLITAN BOROUGH COUNCIL This matter is a Key Decision within the Council s definition and has been included in the relevant Forward Plan Report of the Executive Director (People) to Cabinet
More informationAchieve. Salford Young People s Service. Salford Recovery
Achieve Salford Young People s Service Achieve Salford Recovery Services Achieve SAlford recovery ServiceS Achieve Salford Recovery Services brings together people from a range of organisations, backgrounds
More informationHepatocellular Carcinoma (HCC): Burden of Disease
Hepatocellular Carcinoma (HCC): Burden of Disease Blaire E Burman, MD VM Hepatology Hepatocellular Carcinoma (HCC) Primary HCCs most often arise in the setting of chronic inflammation, liver damage, and
More informationPromoting hepatitis B vaccination
Promoting hepatitis B vaccination Introduction Hepatitis B is a serious blood borne infection that can exacerbate hepatitis C infection, can cause serious liver damage and sometimes results in death. Hepatitis
More informationTreatment of Hepatitis C. David Beking, BHSc, MPH Street Health Centre, Kingston ON Canadian Journal of Gastroenterology (accepted Sept.
Treatment of Hepatitis C among IDUs: A multidisciplinary care approach David Beking, BHSc, MPH Street Health Centre, Kingston ON Canadian Journal of Gastroenterology (accepted Sept. 2012) Public health
More informationPrevention of and Immunisation against Hepatitis B and C
Prevention of and Immunisation against Hepatitis B and C January 2014 Quality Education for a Healthier Scotland 1 Learning Outcomes Participants will be able to:- Demonstrate an increased knowledge and
More informationAddictions and the liver
Addictions and the liver John Logan Consultant t in Public Health Medicine i NHS Lanarkshire BBV Executive Lead Co-chair, Sexual Health & BBV Executive e Leads Group john.logan@lanarkshire.scot.nhs.uk
More informationExploring the risks of liver cancer after successful treatment for hepatitis C virus
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring the risks of liver cancer after successful treatment for hepatitis C virus 11 June 2013 In Canada and other high-income countries,
More informationHepatitis C Hepatitis C
Hepatitis C NHS Dumfries & Galloway would like to acknowledge NHS Greater Glasgow for the use of information contained in this leaflet. This leaflet is also available on request in other formats by phoning
More informationPrevention of and Immunisation against Hepatitis B and C
Prevention of and Immunisation against Hepatitis B and C Presentation 5 October 2018 0 Learning Outcomes Participants will be able to: Demonstrate an increased knowledge and understanding of opportunities
More informationHCV Action Kent Hepatitis C Good Practice Roadshow 5 September 2018 SUMMARY REPORT
HCV Action Kent Hepatitis C Good Practice Roadshow 5 September 2018 SUMMARY REPORT Introduction HCV Action and Public Health England (PHE) staged the second hepatitis C good practice roadshow of 2018 in
More information1. RE-COMMISSIONING OF DRUG AND ALCOHOL TREATMENT AND RECOVERY SERVICES
Cabinet Member Decision 7 August 2014 1. RE-COMMISSIONING OF DRUG AND ALCOHOL TREATMENT AND RECOVERY SERVICES Relevant Cabinet Member Relevant Officer Recommendation Mr M J Hart Director of Adult Services
More informationPegylated Interferons and Ribavirins
Pegylated Interferons and Ribavirins Goal(s): Cover drugs only for those clients where there is evidence of effectiveness and safety Length of Authorization: 16 weeks plus 12-36 additional weeks or 12
More informationCuring Hepatitis C: Current And Future Options For Treatment By Gregory T. Everson, Gene Schiff READ ONLINE
Curing Hepatitis C: Current And Future Options For Treatment By Gregory T. Everson, Gene Schiff READ ONLINE AASLD president will discuss current hepatitis B treatment options, to hepatitis C research,
More informationAASLD, Boston, USA, 10 th November 2014 [oral presentation]
Effects of Sustained Virological Response on the of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34,563 patients with Hepatitis C infection. Andrew
More informationThe contribution of applied psychologists to recovery oriented substance misuse treatment systems
The contribution of applied psychologists to recovery oriented substance misuse treatment systems Dr. Christopher Whiteley Consultant Clinical Psychologist South London & Maudlsey NHS Foundation Trust
More informationWomen s Experiences of Recovery from Substance Misuse
Women s Experiences of Recovery from Substance Misuse A review of women s only group therapy I have got my life back. The group provided me with a safe haven. It was for the first time in years that I
More informationNew hepatitis C medicines Frequently Asked Questions
New hepatitis C medicines Frequently Asked Questions The Minister for Health, the Hon Sussan Ley MP, announced on 20 December 205, that a number of new medicines would be made available through the Pharmaceutical
More informationGlobal reporting system for hepatitis (GRSH) data approval manual
Global reporting system for hepatitis (GRSH) data approval manual Contents Acknowledgement... 1 General information... 2 1. Logging in... 2 2. Validating aggregated numbers in the reports application...
More informationGuidelines For Services Providing Injecting Equipment
Guidelines For Services Providing Injecting Equipment Best Practice Recommendations For Commissioners and Injecting Equipment Provision (IEP) Services in Scotland (Scottish Government 2010) January 2014
More informationWHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT
WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT October 13, 2016 Reminder - treatment is recommended for all patients with chronic HCV infection Except short life expectancies that cannot be remediated
More informationSubstance misuse: dual diagnosis, taking steps to improve care
Substance misuse: dual diagnosis, taking steps to improve care Presented by: Kerry Trinder, Head of Services for the Black Country Marcin Parakoyi MRCPsych, Consultant Psychiatrist Date: 20 th September
More informationDeterminants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus
Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus Leah Burke, M.D. 1, Daniel Fierer, M.D. 2, David Cassagnol,
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationHepatitis C: Ribavirin/Pegylated Interferon combination therapy
Hepatitis C: Ribavirin/Pegylated Interferon Introduction This information sheet is for people who want to know more about the ribavirin/pegylated interferon combination treatment for Hepatitis C (HCV).
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationHepatitis C The NHS Model. Professor Graham R Foster Professor of Hepatology Barts Liver Centre QMUL
Hepatitis C The NHS Model Professor Graham R Foster Professor of Hepatology Barts Liver Centre QMUL The NHS Approach Background The strategy Tactics The NHS Approach Background The strategy Tactics NHSE
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationNeeds Assessment 2011
Young People s Substance Misuse Needs Assessment 2011 Part 2: An Overview of Young People in Treatment for Substance Misuse in Somerset May 2012 Produced by the Partnership Intelligence Unit on behalf
More informationHepatitis C Policy Discussion
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationHIV and Hepatocellular Carcinoma. Dr Kosh Agarwal Institute of Liver Studies King s College Hospital Rome May 2013
HIV and Hepatocellular Carcinoma Dr Kosh Agarwal Institute of Liver Studies King s College Hospital Rome May 2013 1 In theory, there is no difference between theory and practice In practice there is Chuck
More informationAnnual statement of progress Liver Disease Delivery Plan May 2017
Annual statement of progress Liver Disease Delivery Plan May 2017 Overview Liver disease is the third most common cause of premature death in the UK and the national liver disease health outcomes are worse
More informationHEPATITIS B ELIMINATION IN ALASKA Lisa Townshend-Bulson, RN, MSN, FNP-C Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium
HEPATITIS B ELIMINATION IN ALASKA Lisa Townshend-Bulson, RN, MSN, FNP-C Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium Anchorage, Alaska USA Goals of My Lecture Highlight the
More informationTime to Eliminate Hepatitis B John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention
Time to Eliminate Hepatitis B John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD, and
More informationPrevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD
Prevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD Hello, my name is Milena Gould Suarez, and today I will present "Prevent Hepatocellular
More informationGeneral Statement for Drugs for the Treatment of Hepatitis C
General Statement for Drugs for the Treatment of Hepatitis C Use the following criteria to determine patient eligibility for subsidisation under the PBS for hepatitis C treating agents. By writing a PBS
More information